How Long Can You Miss a Wegovy Dose Before It Matters?

The five-day window: where the guidance comes from

The NHS patient information for semaglutide sets a concrete threshold: take a missed dose if your next scheduled injection is still at least five days away. If it's fewer than five days away, the missed dose is left out and you resume as planned. This mirrors the semaglutide Summary of Product Characteristics published on the eMC, which underpins UK prescribing practice.

Why five days specifically? Semaglutide has a half-life of approximately one week, which is precisely why once-weekly dosing works. That long half-life also means a single missed dose doesn't immediately undo the medicine's effect, there is still active drug in circulation. Missing one injection is, in pharmacokinetic terms, less disruptive than it might feel. The catch is that "less disruptive" is not the same as "inconsequential", particularly if gaps become a pattern.

People sometimes find doses slip around bank holidays, a long weekend away, or a period when the routine that helps them remember (first thing Monday morning, say) gets broken. One missed dose handled correctly rarely changes the clinical trajectory. A string of them can. The full guidance on what to do if you miss a Wegovy dose gives the practical steps for each situation.

What happens when the gap extends beyond one week

A gap of more than seven days (meaning you've missed your dose and your usual next injection day has also passed without one) sits in different territory. You're now more than one full dosing interval behind.

At this point, appetite-regulating signals that semaglutide suppresses can begin to reassert themselves. Gastric emptying speeds up slightly. Some people notice hunger returning, or food feeling less satiating than it had. This isn't dramatic or immediate, but it is measurable, and it's the reason the clinical framework around long-term Wegovy use emphasises consistent weekly dosing as a core part of treatment efficacy.

The STEP 1 trial, published in the New England Journal of Medicine, achieved approximately 15% average weight reduction at 68 weeks with 2.4mg semaglutide weekly, a result that depended on sustained, regular dosing alongside lifestyle changes. Trial participants who missed doses more frequently showed attenuated responses. Consistency isn't incidental to the result; it is part of the mechanism.

If a week-long gap has occurred, most people can resume their scheduled dose on their usual day and continue from there. But if you've been off the medicine for two weeks or more, talk to your prescriber before resuming. Restarting at the same dose after an extended break can increase the likelihood of gastrointestinal side effects.

Two weeks or more away: when a dose reduction may be needed

A gap of fourteen days or longer is where clinical caution becomes most relevant. The SmPC advises that after a break of this length, restarting at a lower dose (working back up through the titration schedule) may be appropriate to reduce tolerability issues. This is not a universal rule that applies identically to every patient; it's a clinical judgement that depends on how long you had been on your current dose, how well you'd tolerated it, and what's caused the gap.

Gastrointestinal side effects (nausea, vomiting, loose stools) are most common at the start of treatment and after each dose increase. A two-week-plus interruption can, in effect, reset some of that tolerance. Jumping straight back to, say, 1.7mg or 2.4mg after a fortnight away risks those early-stage symptoms returning with more intensity than they would have at a lower reintroduction dose.

Your prescriber is the right person to make this call. If you're a nume patient, our clinical team is available seven days a week via the aftercare support channel, exactly this kind of question is what aftercare exists for. Understanding where you are in the full Wegovy dose schedule matters here, because the implications of a break at 0.5mg look different from a break at the maintenance dose.

Practical considerations: eligibility, cost and restarting

A common practical scenario: someone partway through treatment runs into a supply gap, a change in circumstances, or a period where the cost isn't manageable for a month. Wegovy is a private prescription in the UK for most patients; the realities of monthly spend mean pauses happen. For context on what private treatment typically involves financially, the guide to accessing Wegovy in the UK covers what's included in a legitimate private prescription service versus what some providers leave out.

If you're restarting after an unplanned gap, the guidance on the Wegovy starting dose is worth reading alongside the advice from your prescriber, because it explains the logic of the titration schedule, which directly informs how to re-enter it. NICE's appraisal of semaglutide for weight management, published as TA875, notes that treatment should be reviewed regularly and continued only where clinically appropriate; any significant gap is a reasonable prompt for that review conversation.

One note on the longer picture: missing doses repeatedly, or stopping and restarting frequently, tends to make the titration process harder, not easier, and can slow progress toward the doses where the clinical evidence is strongest. Check your eligibility and talk to a prescriber if you're unsure whether to restart, step down, or continue where you left off.